Theratechnologies to Present Preliminary Safety and Efficacy

Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses and seven patients with prolonged stable disease Efficacy and tolerability data from dose escalation and... | May 25, 2023

Related Keywords

Chicago , Illinois , United States , Montreal , Quebec , Canada , Texas , American , Julie Schneiderman , Christian Marsolais , Philippe Dubuc , Communications Corporate Affairs , Theratechnologies Inc , University Of Texas Md Anderson Cancer Center , American Society Of Clinical Oncology , Drug Administration , Department Of Investigational Cancer Therapeutics , American Society , Clinical Oncology , Senior Vice President , Chief Medical Officer , Funda Meric Bernstam , Investigational Cancer Therapeutics , Saturday June , Developmental Therapeutics , Targeted Agents , Tumor Biology , Sudocetaxel Zendusortide , Fast Track , Forward Looking Statements , Looking Statements , Annual Information Form , Vice President , Chief Financial , Theratechnologies Inc Stock Exchange , News , Information , Press Release , Reliminary , Signs , F , Antitumor , Activity , Oted , N , Ith , Two , Artial , Responses , End , Seven , Patients , Bprolonged , Table , Disease , Efficacy , Tolerability , Data , Rom , Nose , Scalation Th Ca88338h1001 ,